Editas Medicine Inc Stock Price, News & Analysis

Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has scheduled a webinar for Tuesday, September 2, 2025, at 8:00 a.m. ET to announce their lead in vivo development candidate. The presentation will be accessible through a webcast link and the company's investor relations website.

The webinar will focus on revealing details about their latest advancement in gene editing technology aimed at developing transformative medicines for serious diseases. A replay will be available in the Investors section of the Editas Medicine website following the presentation.

Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced its participation in three major healthcare investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York featuring a fireside chat at 11:30 a.m. ET, and the Baird Global Healthcare Conference on September 9 in New York.

Live webcasts of available presentations can be accessed through the Investors section of Editas Medicine's website, with replays available for approximately 30 days after each event.

[]

Editas Medicine (Nasdaq: EDIT) reported Q2 2025 financial results and business updates. The company plans to select its first in vivo development candidate in September, targeting an IND filing by mid-2026 and human proof-of-concept by year-end 2026. Key highlights include the acceptance of first IND/CTA for CD19 HD Allo CAR T program with Bristol Myers Squibb and presentation of promising preclinical data at multiple scientific conferences.

Financial results show a net loss of $53.2 million ($0.63 per share), improved from $67.6 million loss in Q2 2024. The company maintains a strong cash position of $178.5 million, providing runway into Q2 2027. Research and development expenses decreased to $16.2 million from $54.2 million year-over-year, while restructuring charges were $26.1 million related to the discontinuation of the reni-cel program.

Editas Medicine (NASDAQ: EDIT) reported promising preclinical data for its in vivo gene editing treatment for sickle cell disease and beta thalassemia. Using proprietary targeted lipid nanoparticle (tLNP) delivery, the company achieved 58% mean editing in hematopoietic stem cells (HSCs) at five months after a single dose in non-human primates, significantly exceeding the 25% threshold needed for therapeutic benefit. The treatment targets HBG1/2 promoters to increase fetal hemoglobin production, mimicking natural mechanisms. Notably, the biodistribution data showed significant liver de-targeting compared to standard LNPs. The data will be presented at the European Hematology Association 2025 Congress in Milan, Italy.

Editas Medicine (NASDAQ: EDIT) announced the acceptance of new preclinical data for presentation at the European Hematology Association (EHA) 2025 Congress in Milan. The study, conducted in non-human primates, demonstrates promising results for their in vivo hematopoietic stem cell (HSC) gene editing program targeting sickle cell disease and beta thalassemia.

Key findings include high-efficiency HSC delivery, therapeutically relevant editing levels in the HBG1/2 promoter region exceeding 25% threshold with a single dose, and favorable biodistribution using Editas' targeted lipid nanoparticle (tLNP) technology. The data shows significant liver de-targeting compared to standard LNPs, supporting further development of their proprietary HSC-tLNP platform.

Editas Medicine (NASDAQ: EDIT) has reported promising new in vivo data for its gene editing therapy targeting sickle cell disease and beta thalassemia. The study demonstrated high efficiency in editing HBG1/2 promoters in hematopoietic stem cells (HSCs) using their proprietary targeted lipid nanoparticle (tLNP) delivery system. Key findings include:

In non-human primates, a single intravenous dose achieved up to 47% HBG1/2 editing levels in HSCs. In humanized mice, the treatment reached 48% editing in long-term HSCs. Both results exceeded the 25% threshold required for therapeutic benefit.

The company's tLNP formulation showed improved liver de-targeting compared to standard LNPs, and utilizes proprietary AsCas12a technology for high-efficiency editing while minimizing off-target effects. The approach mimics naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH).

Editas Medicine (NASDAQ: EDIT) presented promising in vivo proof of concept data for an undisclosed liver target at the ASGCT Annual Meeting. The study demonstrated successful gene editing using lipid nanoparticles with CRISPR/Cas RNA cargo. Key results include:

• ~70% maximal liver editing and >80% disease biomarker reduction in mouse models
• >50% target gene editing and >15-fold protein upregulation in cynomolgus monkey hepatocytes

The editing strategy mimics a naturally occurring protective variant to upregulate the target gene. The company plans to reveal the specific disease target and development candidate later in 2025. Additional data will be presented at the TIDES USA 2025 Conference.

Editas Medicine (NASDAQ: EDIT) reported Q1 2025 financial results and business updates. The company posted a net loss of $76.1 million ($0.92/share) compared to $62.0 million in Q1 2024. Cash position stands at $221.0 million, providing runway into Q2 2027. Key highlights include upcoming presentations of preclinical data at ASGCT, demonstrating successful use of targeted lipid nanoparticles for gene editing delivery. The company appointed Amy Parison as CFO and remains on track to declare two in vivo gene editing development candidates in mid-2025. Research and development expenses decreased to $26.6 million from $48.8 million YoY, while restructuring charges of $40.9 million were recorded related to the discontinuation of the reni-cel program.

Editas Medicine (NASDAQ: EDIT) announced that the U.S. Court of Appeals for the Federal Circuit has partially affirmed and partially vacated the Patent Trial and Appeal Board's (PTAB) previous decision regarding CRISPR/Cas9 patent interference. The case involves patents between the University of California, University of Vienna, and Emmanuelle Charpentier versus the Broad Institute.

The company emphasized that its in-licensed CRISPR/Cas12a patents are unaffected by this decision. Editas holds exclusive licenses to Harvard and Broad Institute's Cas9 patent estates for human medicine development. The company maintains a robust IP portfolio including fundamental patents for both CRISPR/Cas12a and CRISPR/Cas9 gene editing in human cells across multiple jurisdictions including the US, Europe, China, and Japan.